Beyond the Basics: A 102-Level Look at Pediatric AD Biologics

In this episode of Cutaneous Miscellaneous, host Nicholas Brownstone, MD, welcomes pediatric dermatologist Lisa Swanson, MD, for a deeper look at advanced systemic therapy in pediatric atopic dermatitis (AD). They begin with a board review of transient skin diseases of the newborn. They cover key conditions including erythema toxicum neonatorum, transient neonatal pustular melanosis, congenital milia, neonatal cephalic pustulosis, eosinophilic pustulosis folliculitis, and the miliaria variants, highlighting cytologic findings, distinguishing features, and treatment considerations. In the main segment, they explore AD biologics in a “102-level” discussion for residents. Dr Swanson reviews patient identification, differences between pediatric and adult treatment decisions, counseling strategies for families, and the impact of AD on growth and quality of life. She also discusses the mechanisms and use of dupilumab, lebrikizumab, tralokinumab, and nemolizumab, offering practical advice on selecting, switching, and discontinuing biologics, as well as insights into building confidence with advanced therapies. Tune in to the full episode for both a high-yield board review and real-world guidance on incorporating systemic therapies into pediatric dermatology, equipping residents with tools for managing complex cases.

There are no comments yet.

Please log in to write the first comment.